Gilead Sciences Inc
(XTER:GIS)
€
114.1
-0.76 (-0.66%)
Market Cap: 143.26 Bil
Enterprise Value: 155.94 Bil
PE Ratio: 17.90
PB Ratio: 6.94
GF Score: 82/100 Gilead Sciences Inc at Leerink Partners Global Biopharma Conference Transcript
Mar 12, 2024 / 02:00PM GMT
Release Date Price:
€68.54
(-0.46%)
Daina Michelle Graybosch
Leerink Partners LLC, Research Division - Senior MD of Immuno-Oncology and Senior Research Analyst
Okay. Good morning, everyone. My name is Daina Graybosch. I am analyst here at Leerink Partners. My team and I cover immuno-oncology and broader. And we -- one of the companies we cover is Gilead, and we're really excited today to host Cindy Perettie from Kite.
Cindy Perettie
Gilead Sciences, Inc. - EVP of Kite
Thank you. It's nice to be here.
Questions & Answers
Daina Michelle Graybosch
Leerink Partners LLC, Research Division - Senior MD of Immuno-Oncology and Senior Research Analyst
And so we're going to jump right in, because it's a busy year and busy week for CAR T. And we're going to talk all elements. So actually, let's start with BCMA. So Kite has licensed Arcellx's BCMA CAR T called Anito-Cel. And I wonder if you could talk about of all the potentially differentiating product attributes for Anito-Cel, which do you think will be most impactful in commercialization?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot